Heteroannelated anthraquinone derivatives for inhibiting cancers
AssigneeNational Defense Medical Center
InventorsHsu-Shan Huang, Tsung-Chih Chen, Tai-Lung Cha
Life of this patent
Estimating the term…
Abstract
Methods and pharmaceutical compositions for treating cancer utilizing compounds characterized by the following structure: and their pharmaceutically acceptable salts.
Claims11
A method for treating cancer in a mammalian subject in need thereof, consisting of:
- inducing apoptosis, inhibiting cancer cell proliferation, or inhibiting telomerase activity in cancer cells of the mammalian subject by administering to the mammalian subject an effective amount of a pharmaceutical composition comprising:
- a compound having the formula (I):
- or pharmaceutically acceptable salts thereof;
- and
- a pharmaceutically acceptable carrier, a diluent, an excipient, or a combination thereof.
A method for inducing apoptosis in a mammalian cancer cell comprising the step of:
- administering to the mammalian cancer cell an effective amount of a pharmaceutical composition comprising:
- anthra[2,1-c][1,2,5]thiadiazole-6,11-dione, or pharmaceutically acceptable salts thereof;
- and a pharmaceutically acceptable carrier, a diluent, an excipient, or a combination thereof.
A method for inhibiting proliferation of a mammalian cancer cell, comprising the step of:
- administering to the cancer cell an effective amount of a pharmaceutical composition comprising:
- anthra[2,1-c][1,2,5]thiadiazole-6,11-dione, or pharmaceutically acceptable salts thereof;
- and a pharmaceutically acceptable carrier, a diluent, an excipient, or a combination thereof.
A method for inducing apoptosis in one or more cancer cells of a mammalian subject, comprising the step of:
- administering to the subject a biologically active amount of a pharmaceutical composition comprising:
- anthra[2,1-c][1,2,5]thiadiazole-6,11-dione, or pharmaceutically acceptable salts thereof;
- and
- a pharmaceutically acceptable carrier, a diluent, an excipient, or a combination thereof.
A method for inhibiting cancer cell proliferation in a mammalian subject comprising the step of:
- administering to one or more cancer cells in the subject a biologically active amount of a pharmaceutical composition comprising:
- anthra[2,1-c][1,2,5]thiadiazole-6,11-dione, or pharmaceutically acceptable salts thereof;
- and
- a pharmaceutically acceptable carrier, a diluent, an excipient, or a combination thereof.
A method for inhibiting a telomerase enzyme's enzymatic activity in a mammalian subject, said method comprising the step of:
- exposing the telomerase of said mammalian subject to a biologically active amount of a pharmaceutical composition comprising:
- anthra[2,1-c][1,2,5]thiadiazole-6,11-dione, or pharmaceutically acceptable salts thereof;
- and
- a pharmaceutically acceptable carrier, a diluent, an excipient, or a combination thereof.
Dependencies are inferred from the claim text.